Contact

Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ First-In-Class Monoclonal Antibody for the Treatment of Human Infertility

Geneva, Switzerland, and Nouzilly, France - September 2, 2020 - Selexis SA and Igyxos announced today that they have entered into a service agreement to develop Igyxos’ first-in-class monoclonal antibody (mAb) drug candidate for the treatment of human infertility. Under the agreement, Igyxos will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance the program to human trials.

Globally, infertility affects approximately 100 million women and men.[1],[2]  In many cases, infertility is related to disorder in gonadotropins, which are hormones responsible for regulating the reproductive cycle. Therapeutic gonadotropins to treat infertility have been the standard of care since the 1960s. By developing a first-in-class mAb that boosts the bioactivity of endogenous and exogenous gonadotropins, Igyxos aims to significantly improve the therapeutic management of men and women suffering from infertility.

“Selexis is thrilled to play a part in Igyxos’ novel therapeutic approach to male and female infertility with an effective treatment that may overcome the long-standing challenges of current methods of addressing the issue,” said Yemi Onakunle, PhD, MBA, Selexis chief business officer. “As experts in cell line development, we are able to quickly and cost-effectively deliver the high-expressing, stable and production-ready research cell banks necessary to help Igyxos reach the clinic faster and gain a competitive edge. We look forward to embarking upon this exciting collaboration.”

Current infertility management remains unsatisfactory with low success rates (only 50% of treated couples have a child after four cycles of hormonal treatments on average), expensive and cumbersome medical treatment protocols with gonadotropins (several injections per week for up to 2 years in men) and low compliance (30% of patients stop during treatment).

“30 million men and 70 million women suffer from infertility worldwide, yet the prospect of a successful outcome remains limited due to a treatment landscape plagued by low success rates, challenging medical treatment protocols and low compliance,” said Pierre-Henry Longeray, CEO at Igyxos. “At Igyxos, we are working tirelessly to bring a new and long-overdue therapeutic option to address this important issue. With Selexis’ track record of success and innovative technologies, we’re excited to leverage their expertise for the advancement of our important drug development program.”

Selexis’ modular SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.

About Selexis SA

Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of seven commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.

About Igyxos

Igyxos’ mission is to develop new and innovative medical and pharmaceutical technologies in the field of human fertility. Igyxos is involved in all phases of development, from the discovery of promising targets to the identification of potential active compounds such as antibodies. The success of its €7.5 million Series A funding led by Bpifrance, through the FABS funds, alongside with Go Capital Amorçage II and Loire Valley Invest Funds managed by Go Capital and the Emergence Innovation II Fund managed by Sofimac Innovation, will allow Igyxos to develop its lead compound and reach clinical proof of concept. www.igyxos.com

###

FOR MORE INFORMATION
– Web               www.selexis.com
– LinkedIn        
www.linkedin.com/company/selexis-sa
– Twitter          
www.twitter.com/SelexisSA
– Facebook       
www.facebook.com/SelexisSA

Media Inquiries for Selexis
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com

Company Inquiries for Selexis
Robert Meister
Head, Corporate Communications
+1 602-953-1716
robert.meister@selexis.com

Company Inquiries for Igyxos
Pierre-Henry Longeray
CEO
+ 33 6 64 28 81 31 (mobile)
+ 33 2 47 42 76 32 (tel)
pierre-henry.longeray@igyxos.com

[1] Boivin J, Bunting L, Collins JA, Nygren KG (2007) International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 22: 1506–1512.

[2] Agarwal A, Mulgund A, Hamada A, Chyatte MR (2015) A unique view on male infertility around the globe. Reprod Biol Endocrinol 13: 37. 

Topics: Corporate

Crown Bio Signals Increased Investment in Digital Transformation with Appointment of New COO

San Diego, Calif - August, 6 2020 - Crown Bioscience today announces the appointment of John Gu as chief operations officer. Mr. Gu will provide leadership in promoting excellence across CrownBio’s global operations, leveraging his deep expertise in digitalization to drive productivity.

Topics: Corporate

New NAFLD/NASH Preclinical Model Data to be Presented at ADA 2020

San Diego, Calif – June 9, 2020 — Crown Bioscience today announced the presentation of new, proprietary NAFLD/NASH preclinical model development data. The data will be available at the American Diabetes Association (ADA) 80th Scientific Sessions, as well as CrownBio’s own complementary virtual event.

Topics: RR & IVD

MBL has concluded the license agreement regarding fully human monoclonal antibodies for four (4) infectious diseases.

NAGOYA, Japan - May 11, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announces today that MBL has concluded the license agreement with China National Biotec Group Co., Ltd. (CNBG) of a subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM) to comprehensively license fully human monoclonal antibodies generated by MBL for four (4) infectious diseases treatment. Under this license agreement, MBL confirms the development plan implemented by CNBG and its progress, and receives a license fee including running royalties as consideration for this license. CNBG
acquires the exclusive license to develop, manufacture, and sell those antibodies and to use related technical know-hows in China and the other Asian regions (excluding Japan), and begin development in China.

The fully human monoclonal antibodies were generated by using MBL’s basic technology of the
SPYMEG* or the phage display technology. The antibodies are expected to help in treating and
preventing pandemic infections including Influenza because of their broadly neutralizing activity.

MBL Launches New ELISA-based Companion Diagnostic Kit for Spinal Muscular Atrophy

NAGOYA, Japan - May 8, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that it has launched an in vitro diagnostic kit for the genetic disease Spinal Muscular Atrophy (SMA). The MEBCDX AAV9 test kit, which was licensed from Quest Diagnostics, was approved on April 27 by the Ministry of Health, Labour and Welfare (MHLW) as a companion diagnostic (CDx) kit for the SMA gene therapy ZolgensmaTM (onasemnogene abeparvovec-xioi) launched by Novartis International AG. The test kit will enable laboratory testing through LSI Medience Corporation starting today. 

Topics: RR & IVD

CrownBio Announces C-Suite Leadership Changes

San Diego, CA - April 14, 2020 - Crown Bioscience has announced the appointment of Jean-Pierre Wery, PhD as executive chairman of the board effective immediately. Dr. Wery will also serve as chief technology officer (CTO) for JSR Life Sciences, LLC.

Topics: Corporate

Medical & Biological Laboratories Co., Ltd. launches real time PCR-based assay kit products for SARS-CoV-2

NAGOYA, Japan - March 23, 2020 - Medical and Biological Laboratories Co., Ltd. (MBL), a JSR Life Sciences company, announced today that its subsidiary company, G&G Science Co., Ltd., has successfully completed development of a real-time PCR assay kit for “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The kit was evaluated with clinical samples provided by the National Institute of Infectious Diseases (NIID). NIID and the Japan Ministry of Health, Labour and Welfare (MHLW) today published that the results of testing with the kit corresponded 100 percent to those of the current NIID system on both positive and negative agreement rates. Therefore, starting immediately, the kit can be used not only for emergency testing being executed under the Infectious Diseases Control Law of Japan, but also for the clinical testing for the coverage of public medical insurance.

Topics: RR & IVD

JSR Life Sciences Company KBI Biopharma, Inc. Promotes Dirk Lange to CEO

Durham, NC - March 2, 2020 - JSR Life Sciences, LLC announced today that Dirk Lange will take over as president and chief executive officer of KBI Biopharma, Inc., a leading contract development and manufacturing organization (CDMO) and JSR Life Sciences affiliate company.  Lange will be responsible for setting KBI’s global vision, defining strategic priorities and ensuring KBI’s continuous focus on quality and innovation. 

Topics: Bioprocess

JSR Life Sciences and GlycoSeLect Enter Licensing and Joint Development Agreement

Sunnyvale, CA, ‐ October 31, 2019 JSR Life Sciences announced today that it has signed a technology licensing and joint development agreement with Dublin, Ireland-based GlycoSeLect, which provides recombinant prokaryotic lectins (RPLs) that enable the selective isolation of glycosylated biomolecules.  The agreement will focus on the development of a glyco-affinity ligand and capture resin.

Topics: Bioprocess

PeptiDream and JSR Begin a Joint Development Program to Identify Peptides Applicable to Affinity Chromatography

TOKYO, JAPAN – September 20, 2019 - JSR Corporation and PeptiDream Inc. have agreed to begin a joint development program to identify peptides applicable to the affinity chromatography*1 process used in the purification of biopharmaceuticals such as antibody therapeutics.

Topics: Bioprocess

JSR Life Sciences, LLC Expands through East Coast Center of Excellence

Sunnyvale, CA – July 11, 2019 – JSR Life Sciences, LLC announced today that it has expanded its footprint and technical capabilities through the opening of its Applications Center of Excellence in Durham, NC.  The new facility provides state-of-the-art laboratory and work space for JSR’s Separations Sciences Group (SSG) to focus on applications development, customer support and training. 

Topics: Bioprocess

JSR Corporation Transfer of Representative Directors

JSR Corporation Transfer of Representative Directors Announcement 

Topics: Corporate

JSR Establishes US Headquarters for JSR Life Sciences and North American Holding Company

SUNNYVALE, CA – Mar. 14, 2019 – JSR announced today that it will establish a US headquarters for its biotechnology and life sciences focused businesses under the name JSR Life Sciences, LLC effective April 1, 2019.  The formation of JSR Life Sciences will centralize leadership and resources to support the company’s value proposition of driving innovation to provide a portfolio of integrated products, services and technologies to help partners develop and commercialize therapeutics and diagnostics that benefit global human health.

Topics: Corporate

Aspect Biosystems Announces Liver Tissue Collaboration with JSR

Vancouver, Canada - September 18, 2018 - Aspect Biosystems, a privately held biotechnology company focused on commercializing cutting-edge bioprinting technologies, is pleased to announce a new collaboration to develop human liver tissue with JSR Corporation, a leading materials supplier in a variety of technology driven markets. Through this collaboration, Aspect’s proprietary Lab-on-a-Printer™ 3D bioprinting platform and JSR’s advanced materials technology will be used to develop vascularized human liver lobules.  

Topics: Corporate

JSR Completes its Amsphere™ A3 Capacity Expansion

Leuven, Belgium – May 17, 2018 – JSR Life Sciences (JLS) is pleased to announce that it has completed its capacity expansion for production of its Amsphere™ A3 protein-A chromatography resin in Leuven, Belgium. The new facility has been built to the highest quality standards using state of the art engineering and is adjacent to JSR’s existing European operations, JSR Micro NV.  

Topics: Bioprocess

Oxford Performance Materials and JSR Corporation Announce Partnership to Advance OPM Technology Platform Throughout Asia

SOUTH WINDSOR, Conn. and TOKYO - May 14, 2018 - Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM®), and Tokyo-based JSR Corporation (JSR), a leading materials supplier in a variety of technology driven markets, today announced a partnership to advance OPM’s poly-ether-ketone-ketone (PEKK)-based 3D-printed orthopedic devices and biomedical & dental materials businesses throughout Asia. 

Topics: Corporate

JSR has exclusively licensed intellectual property for the treatment and diagnosis of inflammatory bowel disease

Tokyo, Japan – January 30, 2018 – JSR Corporation has been granted an exclusive license for intellectual property from Keio University for the treatment and diagnosis of inflammatory bowel disease (IBD). JSR then granted exclusive licenses of the key intellectual property to BiomX Ltd., a microbiome drug discovery company developing customized phage therapies, to develop and commercialize phage therapies based on the intellectual property. 

Topics: RR & IVD

JSR Announces Acquisition of Crown Biosciences International

TOKYO – Dec. 20, 2017 – JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research.  This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capabilities

Topics: Corporate

JSR Life Sciences Agrees to Acquire Pioneering Cell Line Developer Selexis SA and Integrate Selexis with KBI Biopharma, Inc.

JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies

Topics: Bioprocess

JSR Life Sciences Expands Manufacturing Capabilities at KBI Biopharma

Durham, NC - May 23, 2017 - JSR Life Sciences (JLS) today announced that KBI Biopharma (KBI), a subsidiary of JSR Corporation (JSR), is expanding its biopharmaceutical manufacturing capacity and capabilities at both its Durham, North Carolina and Boulder, Colorado facilities.  KBI is investing approximately $30M on the two site expansion projects, which will greatly enhance the offerings at each site and are scheduled for completion later this year.

Topics: Bioprocess

JSR Corporation Establishes JSR Life Sciences Division, Names North American Leader

April 14, 2016 – Sunnyvale, CA – JSR Life Sciences Division (JLS) today announced the formation and establishment of its global corporate headquarters in Sunnyvale, CA USA. Eric R. Johnson will assume responsibility of all operations as Senior Executive Officer and General Manager Life Sciences Division. JLS US headquarters will be responsible for all commercial business activities including strategic planning, customer support, marketing and product development oversight.

Topics: Corporate

Featured